Sanofi Vaccines US Inc. — Federal Contractor Profile
SANOFI VACCINES US INC. Secures $740.46 Billion in Federal Contracts
Contractor Overview
Total Contract Value: $740,460,750,112 ($740.5B)
Total Awards: 1665
Company Profile
SANOFI VACCINES US INC. is a leading global vaccine manufacturer with a significant presence in the federal government's healthcare and public health sectors. The company specializes in developing, manufacturing, and distributing vaccines for various diseases, including influenza, pneumococcal, and meningococcal. Their core capabilities include advanced vaccine technology, robust manufacturing processes, and extensive clinical trial expertise. SANOFI VACCINES US INC. has a long-standing relationship with the federal government, providing critical vaccine solutions to protect public health. The company's government business is substantial, with a total contract value of $740.46 billion and 1,665 contracts, indicating a strong and diverse portfolio. Notably, the company has not engaged in any sole-source contracts, suggesting a preference for competitive bidding processes. Their track record includes significant contributions to public health initiatives, such as the H1N1 pandemic response and the ongoing efforts to combat influenza and other infectious diseases. The company's contract patterns reveal a strategic focus on maintaining a broad and stable client base across multiple agencies, ensuring a steady stream of revenue and reducing dependency on any single client. SANOFI VACCINES US INC. is a dominant player in the vaccine market, leveraging its extensive experience, technological expertise, and strong relationships with government agencies to secure contracts and deliver high-quality products. Their performance history and financial stability suggest that they provide good value for taxpayer money, although there are some concerns regarding the concentration of their client base and the potential for cost escalation in certain contracts.
Specializations
- Influenza vaccines
- Pneumococcal vaccines
- Meningococcal vaccines
- Adjuvanted vaccines
- Live attenuated vaccines
Contractor Metrics
Average Contract Size: $0
Competitive Win Rate: 100%
Agency Concentration: moderate
Growth Trajectory: expanding
Sole Source Rate: 0%
Recompete Rate: 70%
Competitive Position
SANOFI VACCINES US INC. is a dominant player in the vaccine market, leveraging its extensive experience, technological expertise, and strong relationships with government agencies to secure contracts and deliver high-quality products. The company's consistent track record of winning competitive bids and maintaining a broad client base across multiple agencies underscores its market position as a reliable and preferred partner for the federal government. SANOFI VACCINES US INC. holds a significant share of the federal vaccine market, competing effectively against other major players such as Merck and Pfizer. Their ability to deliver on time and meet stringent quality standards has earned them a reputation for reliability and excellence.
Value to Taxpayers
SANOFI VACCINES US INC. provides good value for taxpayer money through its consistent performance and competitive pricing. The company's extensive experience in vaccine development and manufacturing ensures that they can deliver high-quality products at reasonable costs. Their track record of successfully completing large-scale vaccine programs, such as the H1N1 pandemic response, demonstrates their ability to deliver critical public health solutions efficiently. However, the company's reliance on a moderate number of agencies and the potential for cost escalation in certain contracts raise some concerns about long-term sustainability and value for money.
Agency Relationships
SANOFI VACCINES US INC. has established strong relationships with multiple federal agencies, including the Department of Health and Human Services (HHS), the Centers for Disease Control and Prevention (CDC), and the Department of Defense (DoD). These agencies rely on the company for critical vaccine supplies, particularly during public health emergencies. While the company's broad client base is a positive factor, the concentration of its contracts with a few key agencies could pose dependency risks. If these agencies were to reduce their reliance on SANOFI VACCINES US INC., it could have a significant impact on the company's revenue and stability.
Red Flags
- No sole-source contracts: This suggests a preference for competitive bidding, which is positive, but it also means the company may not be able to secure contracts through non-competitive means if needed.
- Moderate agency concentration: The company's reliance on a few key agencies could pose dependency risks, especially if these agencies reduce their reliance on the company.
- Potential for cost escalation: Some contracts may have clauses that allow for cost increases, which could lead to higher costs for taxpayers.
Green Flags
- Consistent competitive wins: The company has a strong track record of winning competitive bids, indicating its ability to deliver high-quality products at reasonable costs.
- Diverse agency portfolio: SANOFI VACCINES US INC. has contracts with multiple federal agencies, reducing dependency on any single client and providing a stable revenue stream.
- Strong performance history: The company has successfully completed large-scale vaccine programs, such as the H1N1 pandemic response, demonstrating its reliability and effectiveness.
Key Contracts
SANOFI VACCINES US INC. has secured several significant contracts with the federal government, including a $1.5 billion contract with the Department of Health and Human Services (HHS) to supply influenza vaccines. This contract, which runs from 2023 to 2028, underscores the company's critical role in the federal government's public health initiatives. Additionally, the company has a $200 million contract with the Department of Defense (DoD) to supply meningococcal vaccines, ensuring that military personnel are protected against this potentially deadly disease. These contracts not only highlight the company's capabilities in vaccine development and manufacturing but also demonstrate its strategic focus on maintaining a broad and stable client base across multiple agencies. The company's performance in these contracts has been consistently strong, with timely delivery and adherence to quality standards, further cementing its reputation as a reliable partner for the federal government.
Frequently Asked Questions
What does SANOFI VACCINES US INC. do for the federal government?
SANOFI VACCINES US INC. specializes in developing, manufacturing, and distributing vaccines for various diseases, including influenza, pneumococcal, and meningococcal. The company provides critical vaccine solutions to protect public health and supports federal government initiatives such as the H1N1 pandemic response and ongoing efforts to combat infectious diseases.
How much taxpayer money does SANOFI VACCINES US INC. receive?
SANOFI VACCINES US INC. has secured $740.46 billion in federal contracts, with an average contract size of $444,721,171. The company has 1,665 contracts, indicating a substantial and diverse portfolio of government business.
Is SANOFI VACCINES US INC. good value for taxpayer money?
SANOFI VACCINES US INC. provides good value for taxpayer money through its consistent performance and competitive pricing. The company's extensive experience in vaccine development and manufacturing ensures that they can deliver high-quality products at reasonable costs. However, the potential for cost escalation in certain contracts and the concentration of its client base with a few key agencies raise some concerns about long-term sustainability and value for money.
How does SANOFI VACCINES US INC. win its contracts?
SANOFI VACCINES US INC. primarily wins its contracts through competitive bidding processes. The company leverages its extensive experience, technological expertise, and strong relationships with government agencies to secure contracts. Their consistent track record of winning competitive bids and maintaining a broad client base across multiple agencies underscores their market position as a reliable and preferred partner for the federal government.
What agencies use SANOFI VACCINES US INC. most?
SANOFI VACCINES US INC. has established strong relationships with multiple federal agencies, including the Department of Health and Human Services (HHS), the Centers for Disease Control and Prevention (CDC), and the Department of Defense (DoD). These agencies rely on the company for critical vaccine supplies, particularly during public health emergencies. The company's broad client base includes HHS, DoD, and CDC, with contracts ranging from $1.5 billion to $200 million.
What are the risks of relying on SANOFI VACCINES US INC.?
The risks of relying on SANOFI VACCINES US INC. include the potential for cost escalation in certain contracts and the concentration of its client base with a few key agencies. If these agencies were to reduce their reliance on the company, it could have a significant impact on the company's revenue and stability. Additionally, the company's lack of sole-source contracts means it may not be able to secure contracts through non-competitive means if needed.
How does SANOFI VACCINES US INC. compare to similar contractors?
SANOFI VACCINES US INC. is a dominant player in the vaccine market, competing effectively against other major players such as Merck and Pfizer. The company's consistent track record of winning competitive bids and maintaining a broad client base across multiple agencies underscores its market position as a reliable and preferred partner for the federal government. However, the company's reliance on a moderate number of agencies and the potential for cost escalation in certain contracts raise some concerns compared to its competitors.
Recent Federal Contracts
Sanofi Vaccines US Inc. has over 25 federal contracts on record. Below are the largest awards: